Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 289


TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).

Bunch B, Krishnan N, Greenspan RD, Ramakrishnan S, Attwood K, Yan L, Qi Q, Wang D, Morrison C, Omilian A, Bshara W, Pili R, Trump DL, Johnson C, Woloszynska A.

Cell Cycle. 2019 Sep;18(17):2055-2066. doi: 10.1080/15384101.2019.1638693. Epub 2019 Jul 18.


Vitamin D3 enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk.

Bunch BL, Ma Y, Attwood K, Amable L, Luo W, Morrison C, Guru KA, Woloszynska-Read A, Hershberger PA, Trump DL, Johnson CS.

Cancer Med. 2019 May;8(5):2449-2461. doi: 10.1002/cam4.2119. Epub 2019 Apr 10.


Calcitriol and cancer therapy: A missed opportunity.

Trump DL.

Bone Rep. 2018 Jun 13;9:110-119. doi: 10.1016/j.bonr.2018.06.002. eCollection 2018 Dec.


Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort.

McDonnell SL, Baggerly CA, French CB, Baggerly LL, Garland CF, Gorham ED, Hollis BW, Trump DL, Lappe JM.

PLoS One. 2018 Jun 15;13(6):e0199265. doi: 10.1371/journal.pone.0199265. eCollection 2018.


Vitamin D in prostate cancer.

Trump DL, Aragon-Ching JB.

Asian J Androl. 2018 May-Jun;20(3):244-252. doi: 10.4103/aja.aja_14_18. Review.


Vitamin D Receptor Signaling and Cancer.

Campbell MJ, Trump DL.

Endocrinol Metab Clin North Am. 2017 Dec;46(4):1009-1038. doi: 10.1016/j.ecl.2017.07.007. Epub 2017 Sep 29. Review.


1,25D3 differentially suppresses bladder cancer cell migration and invasion through the induction of miR-101-3p.

Ma Y, Luo W, Bunch BL, Pratt RN, Trump DL, Johnson CS.

Oncotarget. 2017 Jul 27;8(36):60080-60093. doi: 10.18632/oncotarget.19629. eCollection 2017 Sep 1.


Targeted therapies in the treatment of urothelial cancers.

Aragon-Ching JB, Trump DL.

Urol Oncol. 2017 Jul;35(7):465-472. doi: 10.1016/j.urolonc.2017.03.011. Epub 2017 Mar 31. Review.


Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing.

Wei L, Papanicolau-Sengos A, Liu S, Wang J, Conroy JM, Glenn ST, Brese E, Hu Q, Miles KM, Burgher B, Qin M, Head K, Omilian AR, Bshara W, Krolewski J, Trump DL, Johnson CS, Morrison CD.

BMC Med Genomics. 2016 Oct 19;9(1):64.


Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational study.

Hinata N, Hussein AA, George S, Trump DL, Levine EG, Omar K, Dasgupta P, Khan MS, Hosseini A, Wiklund P, Guru KA.

BJU Int. 2017 Apr;119(4):605-611. doi: 10.1111/bju.13678. Epub 2016 Nov 18.


Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.

Aragon-Ching JB, Trump DL.

Future Oncol. 2016 Sep;12(17):2049-58. doi: 10.2217/fon-2016-0155. Epub 2016 Jun 16. Review.


Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib.

Wei L, Liu S, Conroy J, Wang J, Papanicolau-Sengos A, Glenn ST, Murakami M, Liu L, Hu Q, Conroy J, Miles KM, Nowak DE, Liu B, Qin M, Bshara W, Omilian AR, Head K, Bianchi M, Burgher B, Darlak C, Kane J, Merzianu M, Cheney R, Fabiano A, Salerno K, Talati C, Khushalani NI, Trump DL, Johnson CS, Morrison CD.

Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000380. doi: 10.1101/mcs.a000380.


The Incidental Use of High-Dose Vitamin D3 in Pancreatic Cancer.

Cannon TL, Ford J, Hester D, Trump DL.

Case Rep Pancreat Cancer. 2016 May 1;2(1):32-35. doi: 10.1089/crpc.2016.0003. eCollection 2016.


Vitamin D Signaling Modulators in Cancer Therapy.

Luo W, Johnson CS, Trump DL.

Vitam Horm. 2016;100:433-72. doi: 10.1016/bs.vh.2015.11.004. Epub 2016 Jan 13.


Mechanistic Insights of Vitamin D Anticancer Effects.

Ma Y, Johnson CS, Trump DL.

Vitam Horm. 2016;100:395-431. doi: 10.1016/bs.vh.2015.11.003. Epub 2016 Jan 13. Review.


Genetic variations in vitamin D-related pathways and breast cancer risk in African American women in the AMBER consortium.

Yao S, Haddad SA, Hu Q, Liu S, Lunetta KL, Ruiz-Narvaez EA, Hong CC, Zhu Q, Sucheston-Campbell L, Cheng TY, Bensen JT, Johnson CS, Trump DL, Haiman CA, Olshan AF, Palmer JR, Ambrosone CB.

Int J Cancer. 2016 May 1;138(9):2118-26. doi: 10.1002/ijc.29954. Epub 2015 Dec 28.


Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.

Pokuri VK, Syed JR, Yang Z, Field EP, Cyriac S, Pili R, Levine EG, Azabdaftari G, Trump DL, Guru K, George S.

Clin Genitourin Cancer. 2016 Feb;14(1):e59-65. doi: 10.1016/j.clgc.2015.09.013. Epub 2015 Oct 3.


Vitamin D Repletion Reduces the Progression of Premalignant Squamous Lesions in the NTCU Lung Squamous Cell Carcinoma Mouse Model.

Mazzilli SA, Hershberger PA, Reid ME, Bogner PN, Atwood K, Trump DL, Johnson CS.

Cancer Prev Res (Phila). 2015 Oct;8(10):895-904. doi: 10.1158/1940-6207.CAPR-14-0403. Epub 2015 Aug 14.


Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP.

Steck SE, Arab L, Zhang H, Bensen JT, Fontham ET, Johnson CS, Mohler JL, Smith GJ, Su JL, Trump DL, Woloszynska-Read A.

PLoS One. 2015 Apr 28;10(4):e0125151. doi: 10.1371/journal.pone.0125151. eCollection 2015.


Structural variation discovery in the cancer genome using next generation sequencing: computational solutions and perspectives.

Liu B, Conroy JM, Morrison CD, Odunsi AO, Qin M, Wei L, Trump DL, Johnson CS, Liu S, Wang J.

Oncotarget. 2015 Mar 20;6(8):5477-89. Review.


New serum biomarkers for prostate cancer diagnosis.

Chadha KC, Miller A, Nair BB, Schwartz SA, Trump DL, Underwood W.

Clin Cancer Investig J. 2014;3(1):72-79.


1α,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells.

Ma Y, Hu Q, Luo W, Pratt RN, Glenn ST, Liu S, Trump DL, Johnson CS.

J Steroid Biochem Mol Biol. 2015 Apr;148:166-71. doi: 10.1016/j.jsbmb.2014.09.020. Epub 2014 Sep 26. Review.


Vitamin D and miRNAs in cancer.

Ma Y, Trump DL, Johnson CS.

Curr Gene Ther. 2014;14(4):269-75. Review.


Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancer.

Ajibade AA, Kirk JS, Karasik E, Gillard B, Moser MT, Johnson CS, Trump DL, Foster BA.

PLoS One. 2014 Feb 26;9(2):e89555. doi: 10.1371/journal.pone.0089555. eCollection 2014.


Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients.

Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, Nesline M, Johnson CS, Koochekpour S, Kohli M, Liu S, Trump DL, Sucheston-Campbell LE, Campbell MJ.

Oncotarget. 2014 Feb 15;5(3):824-40.


Combined effects of circulating levels of 25-hydroxyvitamin d and Th1 and th2 cytokines on breast cancer estrogen receptor status.

Yao S, Hong CC, McCann SE, Zirpoli G, Quan L, Gong Z, Johnson CS, Trump DL, Ambrosone CB.

Cancers (Basel). 2014 Jan 27;6(1):211-25. doi: 10.3390/cancers6010211.


Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer.

Morrison CD, Liu P, Woloszynska-Read A, Zhang J, Luo W, Qin M, Bshara W, Conroy JM, Sabatini L, Vedell P, Xiong D, Liu S, Wang J, Shen H, Li Y, Omilian AR, Hill A, Head K, Guru K, Kunnev D, Leach R, Eng KH, Darlak C, Hoeflich C, Veeranki S, Glenn S, You M, Pruitt SC, Johnson CS, Trump DL.

Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):E672-81. doi: 10.1073/pnas.1313580111. Epub 2014 Jan 27.


Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges.

Liu B, Morrison CD, Johnson CS, Trump DL, Qin M, Conroy JC, Wang J, Liu S.

Oncotarget. 2013 Nov;4(11):1868-81. Review.


6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer.

Shen H, Morrison CD, Zhang J, Underwood W 3rd, Yang N, Frangou C, Eng K, Head K, Bollag RJ, Kavuri SK, Rojiani AM, Li Y, Yan L, Hill A, Woloszynska-Read A, Wang J, Liu S, Trump DL, Candace JS.

Oncotarget. 2013 Nov;4(11):2124-34.


Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia.

Lee HJ, Muindi JR, Tan W, Hu Q, Wang D, Liu S, Wilding GE, Ford LA, Sait SN, Block AW, Adjei AA, Barcos M, Griffiths EA, Thompson JE, Wang ES, Johnson CS, Trump DL, Wetzler M.

Cancer. 2014 Feb 15;120(4):521-9. doi: 10.1002/cncr.28368. Epub 2013 Oct 25.


Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer.

Rehman S, Crane A, Din R, Raza SJ, Shi Y, Wilding G, Levine EG, George S, Pili R, Trump DL, Guru KA.

Urology. 2013 Dec;82(6):1370-5. doi: 10.1016/j.urology.2013.07.055. Epub 2013 Oct 11.


Isolation and genome-wide expression and methylation characterization of CD31+ cells from normal and malignant human prostate tissue.

Luo W, Hu Q, Wang D, Deeb KK, Ma Y, Morrison CD, Liu S, Johnson CS, Trump DL.

Oncotarget. 2013 Sep;4(9):1472-83.


Penile cancer: Clinical Practice Guidelines in Oncology.

Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 May 1;11(5):594-615.


Bladder cancer.

Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M; National Comprehensive Cancer Network (NCCN).

J Natl Compr Canc Netw. 2013 Apr 1;11(4):446-75.


Serum vitamin D metabolites in colorectal cancer patients receiving cholecalciferol supplementation: correlation with polymorphisms in the vitamin D genes.

Muindi JR, Adjei AA, Wu ZR, Olson I, Huang H, Groman A, Tian L, Singh PK, Sucheston LE, Johnson CS, Trump DL, Fakih MG.

Horm Cancer. 2013 Aug;4(4):242-50. doi: 10.1007/s12672-013-0139-9. Epub 2013 Feb 28.


A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer.

Ramnath N, Daignault-Newton S, Dy GK, Muindi JR, Adjei A, Elingrod VL, Kalemkerian GP, Cease KB, Stella PJ, Brenner DE, Troeschel S, Johnson CS, Trump DL.

Cancer Chemother Pharmacol. 2013 May;71(5):1173-82. doi: 10.1007/s00280-013-2109-x. Epub 2013 Feb 23.


Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system.

Ma Y, Yu WD, Hidalgo AA, Luo W, Delansorne R, Johnson CS, Trump DL.

Cell Cycle. 2013 Mar 1;12(5):743-52. doi: 10.4161/cc.23846. Epub 2013 Feb 6.


Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells.

Luo W, Yu WD, Ma Y, Chernov M, Trump DL, Johnson CS.

Cancer Res. 2013 Apr 1;73(7):2289-97. doi: 10.1158/0008-5472.CAN-12-4119. Epub 2013 Jan 28.


24-Hydroxylase in cancer: impact on vitamin D-based anticancer therapeutics.

Luo W, Hershberger PA, Trump DL, Johnson CS.

J Steroid Biochem Mol Biol. 2013 Jul;136:252-7. doi: 10.1016/j.jsbmb.2012.09.031. Epub 2012 Oct 8. Review.


Regulation of motility, invasion, and metastatic potential of squamous cell carcinoma by 1α,25-dihydroxycholecalciferol.

Ma Y, Yu WD, Su B, Seshadri M, Luo W, Trump DL, Johnson CS.

Cancer. 2013 Feb 1;119(3):563-74. doi: 10.1002/cncr.27531. Epub 2012 Jul 25.


The role of vitamin D in cancer prevention and treatment.

Krishnan AV, Trump DL, Johnson CS, Feldman D.

Rheum Dis Clin North Am. 2012 Feb;38(1):161-78. doi: 10.1016/j.rdc.2012.03.014. Epub 2012 Apr 12.

Supplemental Content

Loading ...
Support Center